Growth hormone and lean tissue catabolism during long-term glucocorticoid treatment

Clin Endocrinol (Oxf). 1992 Feb;36(2):161-4. doi: 10.1111/j.1365-2265.1992.tb00951.x.

Abstract

Objectives: The aim of the study was to determine whether growth hormone (GH) treatment decreased net protein catabolism of lean tissues in patients receiving chronic glucocorticoid treatment.

Design: Whole body leucine kinetics were measured in post-absorptive conditions using a 1-14C-leucine infusion before and during GH administration (0.0125 mg/kg/day; 0.033 U/kg/day) for 7 days.

Patients: We studied four patients (age range 31-71 years) who had taken prednisone (mean +/- SEM 0.21 +/- 0.03 mg/kg/day, total dose 10-27.5 mg/day) for longer than 5 months for various lung diseases.

Results: During GH treatment leucine oxidation decreased (baseline 0.44 +/- 0.07 vs GH 0.37 +/- 0.05 mumol/kg lean body mass/min, P = 0.01) and non-oxidative leucine disposal increased (1.95 +/- 0.10 vs 2.05 +/- 0.09 mumol/kg lean body mass/min, P = 0.02) but leucine appearance was unaltered.

Conclusions: We conclude that GH decreased amino acid catabolism and improved protein synthesis without altering protein breakdown in patients receiving chronic glucocorticoid treatment. There may be a role for GH in mitigating the protein catabolic side-effects of prolonged glucocorticoid treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Body Composition / drug effects
  • Caproates / blood
  • Female
  • Growth Hormone / therapeutic use*
  • Humans
  • Keto Acids / blood
  • Leucine / metabolism
  • Lung Diseases / blood
  • Lung Diseases / drug therapy*
  • Lung Diseases / metabolism
  • Male
  • Middle Aged
  • Nitrogen / metabolism
  • Prednisolone / therapeutic use*
  • Proteins / metabolism*
  • Time Factors

Substances

  • Caproates
  • Keto Acids
  • Proteins
  • alpha-ketoisocaproic acid
  • Growth Hormone
  • Prednisolone
  • Leucine
  • Nitrogen